vs
Galecto, Inc.（GLTO）与Lakeshore Acquisition III Corp.（LCCC）财务数据对比。点击上方公司名可切换其他公司
Galecto, Inc.的季度营收约是Lakeshore Acquisition III Corp.的1.4倍（$1.0M vs $717.3K），Lakeshore Acquisition III Corp.净利率更高（67.9% vs -20053.5%，领先20121.4%）
Galecto是一家生物科技公司，专注研发针对重症治疗的小分子药物，覆盖纤维化、癌症与炎症等治疗领域。公司由来自瑞典、英国、丹麦的半乳糖凝集素研究权威与生物科技行业高管于2011年创立，目前注册地位于美国，运营总部设在丹麦哥本哈根。
GLTO vs LCCC — 直观对比
营收规模更大
GLTO
是对方的1.4倍
$717.3K
净利率更高
LCCC
高出20121.4%
-20053.5%
损益表 — Q4 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $1.0M | $717.3K |
| 净利润 | $-200.7M | $486.8K |
| 毛利率 | — | — |
| 营业利润率 | -20149.5% | -32.1% |
| 净利率 | -20053.5% | 67.9% |
| 营收同比 | 339.0% | — |
| 净利润同比 | -2877.8% | — |
| 每股收益（稀释后） | $10.86 | $0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收GLTOLCCC
| Q4 25 | $1.0M | — | ||
| Q3 25 | — | $717.3K | ||
| Q2 25 | — | $467.3K | ||
| Q4 24 | $228.0K | — | ||
| Q3 24 | $146.0K | — | ||
| Q2 24 | $213.0K | — | ||
| Q1 24 | $257.0K | — | ||
| Q4 23 | $340.0K | — |
净利润GLTOLCCC
| Q4 25 | $-200.7M | — | ||
| Q3 25 | — | $486.8K | ||
| Q2 25 | — | $216.5K | ||
| Q4 24 | $-6.7M | — | ||
| Q3 24 | $-3.9M | — | ||
| Q2 24 | $-5.3M | — | ||
| Q1 24 | $-5.5M | — | ||
| Q4 23 | $-6.5M | — |
营业利润率GLTOLCCC
| Q4 25 | -20149.5% | — | ||
| Q3 25 | — | -32.1% | ||
| Q2 25 | — | -53.7% | ||
| Q4 24 | -3114.9% | — | ||
| Q3 24 | -2630.1% | — | ||
| Q2 24 | -2618.3% | — | ||
| Q1 24 | -2233.9% | — | ||
| Q4 23 | -1962.1% | — |
净利率GLTOLCCC
| Q4 25 | -20053.5% | — | ||
| Q3 25 | — | 67.9% | ||
| Q2 25 | — | 46.3% | ||
| Q4 24 | -2956.6% | — | ||
| Q3 24 | -2659.6% | — | ||
| Q2 24 | -2506.1% | — | ||
| Q1 24 | -2131.1% | — | ||
| Q4 23 | -1904.4% | — |
每股收益（稀释后）GLTOLCCC
| Q4 25 | $10.86 | — | ||
| Q3 25 | — | $0.08 | ||
| Q2 25 | — | $0.06 | ||
| Q4 24 | $-5.17 | — | ||
| Q3 24 | $-3.39 | — | ||
| Q2 24 | $-4.92 | — | ||
| Q1 24 | $-5.05 | — | ||
| Q4 23 | $-27.66 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $257.6M | — |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $240.4M | $-1.6M |
| 总资产 | $260.5M | $71.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资GLTOLCCC
| Q4 25 | $257.6M | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q4 24 | $14.2M | — | ||
| Q3 24 | $19.7M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $27.2M | — | ||
| Q4 23 | $33.2M | — |
股东权益GLTOLCCC
| Q4 25 | $240.4M | — | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-1.4M | ||
| Q4 24 | $15.8M | — | ||
| Q3 24 | $20.9M | — | ||
| Q2 24 | $23.6M | — | ||
| Q1 24 | $28.2M | — | ||
| Q4 23 | $32.3M | — |
总资产GLTOLCCC
| Q4 25 | $260.5M | — | ||
| Q3 25 | — | $71.0M | ||
| Q2 25 | — | $70.5M | ||
| Q4 24 | $17.1M | — | ||
| Q3 24 | $23.4M | — | ||
| Q2 24 | — | — | ||
| Q1 24 | $32.5M | — | ||
| Q4 23 | $38.2M | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $566.0K | $-206.3K |
| 自由现金流经营现金流 - 资本支出 | — | — |
| 自由现金流率自由现金流/营收 | — | — |
| 资本支出强度资本支出/营收 | — | — |
| 现金转化率经营现金流/净利润 | — | -0.42× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流GLTOLCCC
| Q4 25 | $566.0K | — | ||
| Q3 25 | — | $-206.3K | ||
| Q2 25 | — | $-218.3K | ||
| Q4 24 | $-4.9M | — | ||
| Q3 24 | $-3.7M | — | ||
| Q2 24 | $-4.1M | — | ||
| Q1 24 | $-5.9M | — | ||
| Q4 23 | $-11.5M | — |
现金转化率GLTOLCCC
| Q4 25 | — | — | ||
| Q3 25 | — | -0.42× | ||
| Q2 25 | — | -1.01× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
